Form 8-K · Current Report · Filed 2024-05-31
Guardant Health Amends Executive Severance Plan
Guardant Health, Inc. has amended its Executive Severance Plan, which now includes revised terms for severance pay and equity awards for its named executive officers. These changes apply to all executive employees and are designed to provide additional compensation in the event of a qualifying termination, whether due to termination by the company without cause, termination by the executive for good reason, or within specific periods relative to a change in control. The amendment also addresses the vesting of equity awards, including restricted stock units (RSUs) and performance restricted stock units (PSUs), for the company's Co-Chief Executive Officers under different termination scenarios.
- Filer
- Guardant Health Inc. GH · NASDAQ
- Filed
- Accession
- 0001193125-24-151836
- CIK
- 0001576280
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Market reaction
Close before filing
$27.47
Next session
-0.2%
Since filing
+489.7%
Latest close
$161.99
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from GH reporting the same item, with the next session's move:
About Guardant Health Inc.
Guardant Health Inc. is an innovative biotechnology company specializing in the development and commercialization of precision oncology diagnostics. This company is recognized for its groundbreaking work in non-invasive cancer detection through liquid biopsy technologies, which involve analyzing circulating tumor DNA in blood samples. Guardant Health’s primary function is to provide oncologists and researchers with critical tools and data to better understand cancer, tailor treatments, and monitor disease progression, potentially improving patient outcomes significantly. Guardant Health operates prominently in the healthcare and biotechnology sector, significantly impacting fields such as cancer research and personalized medicine. Their products and services are vital for facilitating early detection of cancer, identifying treatment options, and offering companion diagnostics for pharmaceutical developments. In the financial market, Guardant Health represents an important player within the precision medicine landscape, influencing investment within the biotechnology and healthcare sectors. Founded in 2012 and headquartered in Redwood City, California, the company continues to expand its portfolio and advance its technologies, playing a pivotal role in the fight against cancer at a global level.
Never miss another GH filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.